Diamond Hill Capital Management Inc. purchased a new position in shares of Endo International PLC (NASDAQ:ENDP) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 488,244 shares of the company’s stock, valued at approximately $5,454,000. Diamond Hill Capital Management Inc. owned about 0.22% of Endo International PLC at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of ENDP. Norges Bank acquired a new position in shares of Endo International PLC during the fourth quarter worth about $26,929,000. Macquarie Group Ltd. boosted its stake in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. Americafirst Capital Management LLC purchased a new stake in shares of Endo International PLC during the first quarter worth about $286,000. Hartford Investment Management Co. purchased a new stake in shares of Endo International PLC during the first quarter worth about $1,363,000. Finally, Nationwide Fund Advisors boosted its stake in shares of Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. 93.00% of the stock is owned by hedge funds and other institutional investors.
Endo International PLC (NASDAQ ENDP) traded up 0.53% during midday trading on Friday, reaching $7.59. 8,959,667 shares of the company traded hands. The firm’s market capitalization is $1.69 billion. Endo International PLC has a one year low of $7.41 and a one year high of $24.93. The firm has a 50-day moving average price of $10.93 and a 200-day moving average price of $11.55.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.86 earnings per share. Equities analysts predict that Endo International PLC will post $3.51 EPS for the current fiscal year.
Several brokerages have recently issued reports on ENDP. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Vetr raised shares of Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price objective on the stock in a research note on Wednesday, May 17th. William Blair reissued a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Zacks Investment Research lowered shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research note on Monday, May 22nd. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the stock. Endo International PLC currently has an average rating of “Hold” and a consensus target price of $14.86.
In other Endo International PLC news, COO Terrance J. Coughlin purchased 20,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were purchased at an average cost of $7.70 per share, with a total value of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.50% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.